Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057707 · ClinicalTrials.gov registry record · Phase 1
Effects of Modafinil on Brain Function in Patients With Schizophrenia
A Phase 1 study, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 1
- Development phase
- 176
- Enrollment target
NCT00057707 is a Phase 1 study that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 176 participants.
The verdict
NCT00057707, a Phase 1 study, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 176 participants
- Enrollment target
Study Summary
This study will evaluate whether modafinil improves cognition in patients with schizophrenia and healthy volunteers. Modafinil is a drug that has been FDA approved for day-time sleepiness and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain ...
Interventions
- DRUG Modafinil
- PROCEDURE Functional MRI
- PROCEDURE Neuropsychological Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2003-03-26 |
| Est. Completion | 2017-06-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00057707
The ClinicalTrials.gov registry entry for NCT00057707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 176 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Modafinil is the first listed.
NCT00057707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00057707 about?
NCT00057707 is a clinical study titled "Effects of Modafinil on Brain Function in Patients With Schizophrenia". This study will evaluate whether modafinil improves cognition in patients with schizophrenia and healthy volunteers. Modafinil is a drug that has been FDA approved for day-time sleepiness and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain ...
What is the current status of trial NCT00057707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 176 participants. The study started on 2003-03-26. Estimated completion is 2017-06-16.
What interventions are being tested in trial NCT00057707?
The interventions under investigation include: Modafinil (DRUG), Functional MRI (PROCEDURE), Neuropsychological Testing (PROCEDURE).
Who is sponsoring clinical trial NCT00057707?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.